CRISPR-Cas9 screen identifies eIF4G2 as a regulator of CD8+ T cell dysfunction
The Journal of Immunology · 01.10.2026 · 215 (10)
DOI: 10.1093/jimmun/vkag187 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 13.10.2026. Verfasst von Erin A Holcomb und 20 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Immunology, University of Michigan School of Medicine, Ann Arbor, MI, United States. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, CRISPR-Cas Systems, Eukaryotic Initiation Factor-4G. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the Ben and Catherine Ivy Foundation Clinical Investigator of the Damon Runyon Cancer Research Foundation, NCI NIH HHS, National Institutes of Health (NIH).
Abstract (Originalsprache)
CD8+ T cells directly target and kill cancer cells and are required for effective antitumor immunity. However, CD8+ T cells may become dysfunctional when exposed to chronic antigen stimulation during cancer. Dysfunction is characterized by reduced proliferation, increased expression of inhibitory receptors, and impaired effector function, yet the genetic mechanisms controlling dysfunction remain poorly understood. Therefore, we developed a murine ex vivo chronic stimulation model that recapitulates features of CD8+ T cell dysfunction observed within the tumor microenvironment. By coupling this system with genome-wide CRISPR-Cas9 loss-of-function screening, we discovered that the progression of murine CD8+ T cells to a dysfunctional state required eIF4G2, a noncanonical mRNA translation factor. Deletion of eIF4G2 restored CD8+ T cell survival and proliferation during chronic stimulation conditions in vitro. Transcriptomic, proteomic, and flow cytometric analyses revealed that eIF4G2 deletion shifts CD8+ T cell phenotype from a dysfunctional state to a proliferative state. eIF4G2 depletion reduced oxidative stress, lipid peroxidation, and accumulation of misfolded protein aggresomes during chronic in vitro stimulation. Finally, eIF4G2-depleted cells mediated enhanced tumor control in a murine model of melanoma. These data suggest that targeting eIF4G2 may promote CD8+ T cell resilience and improve therapeutic antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Program in Immunology, University of Michigan School of Medicine, Ann Arbor, MI, United States.
- Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI, United States.
- Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, United States.
- Department of Biological Chemistry, University of Michigan, Ann Arbor, MI, United States.
- Cayman Chemical Company, Ann Arbor, MI, United States.
- Department of Pharmacology, University of Michigan School of Medicine, Ann Arbor, MI, United States.
ORCID-Profile: Ashley N Pearson, John R Prensner
Förderung
- the Ben and Catherine Ivy Foundation Clinical Investigator of the Damon Runyon Cancer Research Foundation
- NCI NIH HHS
- National Institutes of Health (NIH)
- NIH
- V Foundation for Cancer Research
- CureSearch Foundation
- U.S. Department of Veterans Affairs
- NIAID NIH HHS
Zitieren
APA
Holcomb, E. A., Jiang, L., Pearson, A. N., James, J., Tate, A., Wang, Z., Dasgupta, A., Clauwaert, J., Armas, N. D., Elaimy, A. L., Palagama, D. S. W., Goodwin, S. K., Kwiatkowski, M. J., Gijón, M., Morgan, M. A., Courtney, A. H., Carty, S. A., Huber, A. K., Zou, W., …, & Green, M. D. (2026). CRISPR-Cas9 screen identifies eIF4G2 as a regulator of CD8+ T cell dysfunction. The Journal of Immunology, 215(10). https://doi.org/10.1093/jimmun/vkag187
Vancouver
Holcomb EA, Jiang L, Pearson AN, James J, Tate A, Wang Z, et al. CRISPR-Cas9 screen identifies eIF4G2 as a regulator of CD8+ T cell dysfunction. The Journal of Immunology. 2026;215(10). doi:10.1093/jimmun/vkag187
BibTeX
@article{Holcomb2026,
author = {Holcomb, Erin A and Jiang, Long and Pearson, Ashley N and James, Jadyn and Tate, Akshay and Wang, Zhuwen and Dasgupta, Anwesha and Clauwaert, Jim and Armas, Nicholas D and Elaimy, Ameer L and Palagama, Dilrukshika S W and Goodwin, Samantha K and Kwiatkowski, Matthew J and Gijón, Miguel and Morgan, Meredith A and Courtney, Adam H and Carty, Shannon A and Huber, Amanda K and Zou, Weiping and Prensner, John R and Green, Michael D},
title = {CRISPR-Cas9 screen identifies eIF4G2 as a regulator of CD8+ T cell dysfunction},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {10},
doi = {10.1093/jimmun/vkag187}
}
EUVIMED